Zynex, Inc. (NASDAQ:ZYXI) Q3 2024 Earnings Conference Call October 24, 2024 4:15 PM ET

Company Participants

Quinn Callanan - IR
Thomas Sandgaard - Chairman, President and CEO
Dan Moorhead - CFO
Donald Gregg - President, Monitoring Solutions

Conference Call Participants

Avi Dahan - RBC Capital Markets
Jeffrey Cohen - Ladenburg Thalmann
Yi Chen - H.C. Wainwright

Operator

Good afternoon, ladies and gentlemen. And welcome to the Zynex Third Quarter 2024 Earnings Conference Call. At this time, all participants are in listen only mode. A question-and-answer session will follow the formal presentation [Operator Instructions]. As a reminder, this conference is being recorded.

I would now like to turn the conference over to Quinn Callanan from MZ North America.

Quinn Callanan

Thank you, operator. And good afternoon, everyone. Earlier today, Zynex released financial results for the third quarter ended September 30, 2024. A copy of the press release is available on the company's Web site. Joining me on today's call are Thomas Sandgaard, Chairman, President and Chief Executive Officer; Dan Moorhead, Chief Financial Officer; and Donald Gregg, President of Zynex Monitoring Solutions. Before we begin, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's 2023 Form 10-K and subsequent Form 10-Qs, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitations, statements regarding product development, product potential, the regulatory environment, sales and marketing strategies, capital resources or operating performance. With that, I'll now turn the call over to Thomas.

Thomas Sandgaard

Thank you, Quinn. And good afternoon, everyone. Thank you for joining us today for the third quarter 2024 earnings call. We are pleased to report on our continued progress as the leading provider of non-opioid pain management solutions and building out cutting edge patient monitoring solutions. We have been successful in diversifying our revenue stream and building a sustainable, profitable company that delivers better pain management and monitoring solutions for patients and doctors as well as hospitals. Our continued revenue growth and sustained profitability that has allowed us to reinvest in our business and return capital to shareholders. I think it's worth reminding the investor community that our 2024 revenue expectation of $200 million is more than 50% higher than we were just three years ago.